Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.020
+0.010 (0.99%)
At close: Jun 26, 2025, 4:00 PM
1.030
+0.010 (0.97%)
After-hours: Jun 26, 2025, 7:31 PM EDT
Esperion Therapeutics Stock Forecast
ESPR's stock price has decreased by -51.2% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts that cover Esperion Therapeutics stock have a consensus rating of "Buy" and an average price target of $5.93, which forecasts a 481.37% increase in the stock price over the next year. The lowest target is $2.5 and the highest is $16.
Price Target: $5.93 (+481.37%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,468.63% | Jun 17, 2025 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +292.16% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,468.63% | Apr 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +390.20% | Apr 25, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +194.12% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
345.84M
from 332.31M
Increased by 4.07%
Revenue Next Year
335.45M
from 345.84M
Decreased by -3.00%
EPS This Year
-0.21
from -0.28
EPS Next Year
-0.24
from -0.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 438.9M | 433.9M | 639.5M | ||
| Avg | 345.8M | 335.5M | 460.9M | ||
| Low | 241.8M | 252.8M | 340.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.1% | 25.5% | 90.6% | ||
| Avg | 4.1% | -3.0% | 37.4% | ||
| Low | -27.2% | -26.9% | 1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.24 | 0.02 | 0.04 | |
| Avg | -0.21 | -0.24 | -0.02 | |
| Low | -0.66 | -0.43 | -0.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.